Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Over 1,500 people from around the world attended MAPS’ Psychedelic Science 2013 conference in Oakland, CA. Rick Doblin, Ph.D.,
Cannabis Law Report
JUNE 10, 2021
We analyzed annual administrations of TSCI from 2013–2017, which asked respondents about various dimensions of traffic safety, including driving after marijuana use [ 28 ]. Between 2013 and 2017, approximately 3000 TSCI surveys were completed annually. 9-tetrahydrocannabinol on driving performance: a randomized clinical trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Since founding Eleusis in 2013, Shlomi has overseen the company’s corporate and clinical development efforts. Shlomi Raz.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 2013 Sep;36(9):2530-5.
Cannabis Law Report
NOVEMBER 24, 2021
Only one article appeared in the MJA in 2000 and again in 2001. Legitimacy framings occur in at least three articles a year between 2013 and 2018 and are most predominant in 2014 and 2019 with a total of five articles in those years. MJA, 16 December 2013). There was one case study and one book review during this period.
Expert insights. Personalized for you.
52 
Let's personalize your content